| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-05-04 | Oncobiologics (USA - NJ) | opening of new premises |
Opening of new premises | |||
| 2015-05-01 | AmpliPhi Biosciences (USA - VA) | nomination |
Infectious diseases | Nomination | ||
| 2015-05-01 | Merck&Co (USA - NJ) PeptiDream (Japan) | macrocylic/constrained peptides | collaboration |
undisclosed | Collaboration agreement | |
| 2015-05-01 | Intarcia Therapeutics (USA - CA) | nomination |
Metabolic diseases | Nomination | ||
| 2015-04-30 | Keryx Biopharmaceuticals (USA - NY) | nomination |
Renal diseases | Nomination | ||
| 2015-04-29 | Bellicum Pharmaceuticals (USA - TX) Leiden University Medical Center | high-affinity TCR (T cell receptor) product candidates targeting solid tumors expressing the preferentially-expressed antigen in melanoma, or PRAME, including BPX-701 and POU-2AF1 | melanoma, sarcomas and neuroblastomas | licensing development production manufacturing commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-04-29 | Evotec (Germany) Facio Therapies (The Netherlands) | small molecules having a positive effect on SMCHD1 and DUX4 activity | facioscapulohumeral dystrophy | collaboration |
Rare diseases - Genetic diseases - Neuromuscular diseases | Collaboration agreement |
| 2015-04-29 | Ariad Pharmaceuticals (USA - MA) | resignation |
Cancer - Oncology | Resignation | ||
| 2015-04-28 | Spark Therapeutics (USA - PA) Clearside Biomedical (USA - GA) | microinjector technology to deliver gene therapies to the back of the eye | licensing |
Ophtalmological diseases | Licensing agreement | |
| 2015-04-28 | Txcell (France) | nomination |
Autoimmune diseases – Inflammatory diseases | Nomination | ||
| 2015-04-28 | RegenXBio (USA - MD) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-04-28 | Serodus (Norway) | nomination |
Cardiovascular diseases - Metabolic diseases | Nomination | ||
| 2015-04-27 | OncoGenex (USA - WA) Teva Pharmaceutical (Israel) | custirsen | prostate cancer, lung cancer | termination |
Cancer - Oncology | Termination of an agreement |
| 2015-04-27 | 4D Molecular Therapeutics (USA - CA) Roche (Switzerland) | next-generation AAV vectors | undisclosed indications with high unmet medical need | licensing collaboration |
undisclosed | Licensing agreement |
| 2015-04-27 | R-Tech Ueno (Japan) Santen Pharmaceutical (Japan) | DE-105 | severe persistent corneal epithelial defects | product acquisition |
Ophtalmological diseases | Product acquisition |
| 2015-04-27 | MaxCyte (USA - MD) Cold Spring Biotech (Taiwan) | MaxCyte STX® and MaxCyte VLX® Large Scale Transfection System | distribution |
Technology - Services | Distribution agreement | |
| 2015-04-27 | Atyr Pharma (USA - CA) | nomination |
Cancer - Oncology - Genetic diseases - Rare diseases | Nomination | ||
| 2015-04-27 | Amicus Therapeutics (USA - NJ) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-04-27 | Moberg Pharma (Sweden) Chattem (USA - TN), a Sanofi company (France) | Balmex® | diaper rash | product acquisition |
Dermatological diseases - Inflammatory diseases | Product acquisition |
| 2015-04-27 | Recipharm (Sweden) | nomination |
Technology - Services | Nomination |
